Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan [2]

Gynecologic Oncology

Volumn 67, Issue 3, 1997, Pages 329-330

  O'Reilly, S ^a   Armstrong, D K ^a   Grochow, L B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

BONE MARROW SUPPRESSION; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG ACCUMULATION; DRUG CLEARANCE; FEMALE; HUMAN; KIDNEY FAILURE; LETTER; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031456165     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4896     Document Type: Editorial

References (4)

1. W ten Bokkel Huinink M Gore J Carmichael A Gordon J Malfetano I Hudson C Broom C Scarabelli N Davidson M Spanczynski G Bolis H Malmstrom R Coleman SC Fields J-F Heron Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 15 1997 2183 2193
2. S O'Reilly EK Rowinsky W Slichenmyer RC Donehower AA Forastiere DS Ettinger TL Chen S Sartorius LB Grochow Phase I and pharmacologic study of topotecan in patients with impaired renal function J Clin Oncol 14 1996 3062 3073
3. RW Jeliffe Creatinine clearance: bedside estimate Ann Intern Med 79 1973 604 605
4. DW Cockcroft MH Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41